


AMENDMENTS TO THE CLAIMS

This listing of Claims will replace all prior versions, and listings, of Claims in the application:

LISTING OF CLAIMS

1. (Previously Presented)

A compound having the formula



wherein

n is an integer from 0 to 4;

R_1 is C_1 to C_6 alkyl or C_3 cycloalkyl;


R_2 and R_3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons, at least one of R_2 and R_3 being other than hydrogen;

R_4 is a heteroaromatic moiety which may be substituted or unsubstituted and is linked to $(CH_2)_n$ via a nitrogen atom or a carbon atom; an amine ($NR'R''$), including those in which the amine is derived from an alpha amino acid of either natural (L) or unnatural (D) stereochemistry; an acylsulphonamide ($CONHSO_2R'$); or a carboxylic acid amide ($CONR'R''$) in which R' and R'' are the same or different and are independently selected from hydrogen, alkyl, aryl, and heteroaryl substituted or unsubstituted with the proviso that when n equals zero ($n=0$), then R_4 can only be a carboxylic acid amide or an acylsulphonamide;

R_5 is hydrogen or an acyl (such as acetyl or benzoyl) or other group capable of bioconversion to generate the free phenol structure (where in $R_5 = H$);

including all stereoisomers thereof, prodrug esters thereof, and pharmaceutically acceptable salts thereof.

2. (Original) A compound as defined in Claim 1 wherein R_4 is a carboxylic acid amide ($\text{CONR}'\text{R}''$) portion of the carboxylic amide can be derived from an achiral or a L or D alpha amino acid such as when the general structure $-\text{CONR}'\text{R}''$ can be represented by



B
J
M

and R' , R'' , R'''' , R''''' , are the same or different and are independently selected from hydrogen, alkyl, aryl and heteroaryl, substituted or unsubstituted, and R^* may be hydrogen, alkyl, aryl and heteroaryl, substituted or unsubstituted, and may also be any of the side chains found in the naturally occurring alpha-amino acids.

3. (Original) The compound in Claim 2 where R' and R^* are connected to form a 4 to 8-membered ring.

4. (Original) The compound as defined in Claim 2 where R' and R^* comprise consecutive $-(\text{CH}_2)-$ groups to form proline or homoprolidine.

5. (Original) The compound as defined in Claim 1 where n is 0, 1, or 2.

6. (Original) The compound as defined in Claim 1 wherein R_2 and R_3 are each independently halogen.

7. (Original) The compound as defined in Claim 1 wherein R_2 and R_3 are each independently an alkyl group.

8. (Original) The compound as defined in Claim 1 wherein one of R_2 and R_3 is halogen and the other is an alkyl group.

9. (Original) The compound as defined in Claim 1 wherein one of R_2 and R_3 is halogen and the other is hydrogen.

10. (Original) The compound as defined in Claim 1 wherein R_2 and R_3 is alkyl and the other is hydrogen.

11. (Original) The compound as defined in Claim 1 wherein R_2 and R_3 are independently Cl, Br, methyl or ethyl.


12. (Original) The compound as defined in Claim 1 wherein R_1 is isopropyl.

13. (Original) The compound as defined in Claim 1 wherein R_4 is heteroaromatic hydrocarbon, carboxylic acid amide, or an acylsulphonamide.












14. (Original) The compound as defined in Claim 1 wherein R_5 is hydrogen.

Claims 15.-16. (Cancelled)


17. (Original) The compound as defined in Claim 1 which is in the table below,



R=



and the compounds indicated in the table below



-NR'R"	Formula
3-(AMINOMETHYL)PYRIDINE	C23H22Br2N2O3
2-(2-AMINOETHYL)PYRIDINE	C24H24Br2N2O3
-NR'R"	Formula
3-(2-AMINOETHYL)PYRIDINE	C24H24Br2N2O3
2-(AMINOMETHYL)PYRIDINE	C24H30Br2N2O3
4-(AMINOMETHYL)PYRIDINE	C24H30Br2N2O3
1-(4-METHOXYPHENYL)PIPERAZINE DIHYDROCHLORIDE	C29H32Br2N2O3
1-(2-FLUOROPHENYL)PIPERAZINE	C34H32Br2N2O3
2-(2-(AMINOMETHYL)PHENYLTHIO)BENZYL ALCOHOL	C31H29Br2N2O4S
2-(1-CYCLOHEXENYL)ETHYLAMINE	C25H29Br2N2O3
2-AMINOINDAN	C26H25Br2N2O3
2-AMINOMETHYLBENZODIOXAN	C26H25Br2N2O5
3-PHENYL-1-PROPYLAMINE	C26H27Br2N2O3
2-(P-TOLYL)ETHYLAMINE	C26H27Br2N2O3
1-(3-AMINOPROPYL)-2-PYRROLIDINONE	C24H28Br2N2O4
BETA-ALANINE 4-METHOXY-BETA-NAPHTHYLAMIDE	C31H30Br2N2O5
2-CHLOROBENZYLAMINE	C24H22Br2ClNO3
2-AMINOMETHYL-3-CHLORODIPHENYLETHER	C30H26Br2ClNO4
DL-ALPHA-AMINO-EPSILON-CAPROLACTAM	C23H26Br2N2O4
L-PHENYLALANINOL	C26H27Br2N2O4
4-(1,2,3-THIADIAZOL-4-YL)BENZYLAMINE	C26H23Br2N3O3S
2-AMINOMETHYLTHIOPHENE	C22H21Br2N2O3S
1-(1-NAPHTHYL)ETHYLAMINE	C29H27Br2N2O3
3-CHLORO-4-METHYL BENZYLAMINE	C25H24Br2ClNO3
TETRAHYDROFURFURYLAMINE	C22H25Br2N2O4
2,4-DICHLOROPHENETHYLAMINE	C25H23Br2Cl2NO3
ETHYL 4-AMINO-1-PIPERIDINECARBOXYLATE	C25H30Br2N2O5
2,6-DIFLUOROBENZYLAMINE	C24H21Br2F2NO3
2-IODOBENZYLAMINE	C24H22Br2I2NO3
2-METHYLBENZYLAMINE	C25H25Br2N2O3
BENZYLAMINE	C24H23Br2N2O3
3-METHYLBENZYLAMINE	C25H26Br2N2O3
2-METHOXYPHENETHYLAMINE	C26H27Br2N2O4
3-METHOXYPHENETHYLAMINE	C26H27Br2N2O4
2-ETHOXYBENZYLAMINE	C26H27Br2N2O4
(R)-(-)-1-CYCLO-HEXYLETHYLAMINE	C25H31Br2N2O3
4-METHOXYPHENETHYLAMINE	C26H27Br2N2O4
2-FLUOROBENZYLAMINE	C24H22Br2F2NO3
2-CHLORO-6-METHYLBENZYLAMINE	C25H24Br2ClNO3
4-CHLOROBENZYLAMINE	C24H22Br2ClNO3

BL

BETA-METHYLPHENETHYLAMINE	C26H27Br2NO3
1,1-DI(P-ANISYL)METHYLAMINE	C32H31Br2NO5
MAYBRIDGE BTB 12133	C27H29Br2NO6
DL-2-AMINO-1-PENTANOL	C22H27Br2NO4
L-PHENYLALANINE P-NITROANILIDE	C32H29Br2N3O6
ETHYL 3-AMINOBUTYRATE	C23H27Br2NO5
(1S,2R)-(+)-2-AMINO-1,2-DIPHENYLETHANOL	C31H29Br2NO4
2-FLUOROPHENETHYLAMINE	C25H24Br2FNO3
2-ETHYLHEXYLAMINE	C25H33Br2NO3
3-FLUOROPHENETHYLAMINE	C25H24Br2FNO3
(1S,2S)-(+)-2-AMINO-3-METHOXY-1-PHENYL-1-PROPANOL	C27H29Br2NO5
NONYLAMINE	C26H35Br2NO3
2,5-DICHLOROBENZYLAMINE	C24H21Br2Cl2NO3
2-METHYLCYCLOHEXYLAMINE	C24H29Br2NO3
3-METHYLCYCLOHEXYLAMINE	C24H29Br2NO3
3-N-PROPOXYPROPYLAMINE	C23H29Br2NO4
2,3-DIMETHYLBENZYLAMINE	C26H27Br2NO3
3-CHLOROBENZYLAMINE	C24H22Br2CINO3
4-TERT-BUTYLCYCLOHEXYLAMINE	C27H35Br2NO3
-NR'R"	Formula
(1S,2S)-(+)-THIOMICAMINE	C27H29Br2NO5S
2,4-DIMETHYLBENZYLAMINE	C26H27Br2NO3
2-AMINOETHYL PHENYL SULFIDE	C25H25Br2NO3S
PHENETHYLAMINE	C25H25Br2NO3
TYRAMINE	C25H25Br2NO4
L-TYROSINE METHYL ESTER	C27H27Br2NO6
BENZHYDROXYLAMINE	C30H27Br2NO3
4-METHOXYBENZYLAMINE	C25H25Br2NO4
2,3-DICHLOROBENZYLAMINE	C24H21Br2Cl2NO3
GLYCINE N-BUTYL ESTER HYDROCHLORIDE	C23H27Br2NO5
D-(+)-ALPHA-PHENYLGLYCINE ETHYL ESTER HYDROCHLORIDE	C27H27Br2NO5
4-CHLORO-2-FLUOROBENZYLAMINE HYDROCHLORIDE	C24H21Br2ClFNO3
TRANS-2-PHENYLCYCLOPROPYLAMINE HYDROCHLORIDE	C26H25Br2NO3
ETHYL 4-AMINOBUTYRATE HYDROCHLORIDE	C23H27Br2NO5
DL-HOMOCYSTEINE THIOLACTONE HYDROCHLORIDE	C21H21Br2NO4S
4-NITROBENZYLAMINE HYDROCHLORIDE	C24H22Br2N2O5
NORPHENYLEPHRINE HYDROCHLORIDE	C25H25Br2NO5
GLYCINE ETHYL ESTER HYDROCHLORIDE	C21H23Br2NO5
DL-ALANINE ETHYL ESTER HYDROCHLORIDE	C22H25Br2NO5
SARCOSINE ETHYL ESTER HYDROCHLORIDE	C22H25Br2NO5
4-NITRO-N-PROPYLBENZYLAMINE HYDROCHLORIDE	C27H28Br2N2O5
PIPERIDINE	C22H25Br2NO3
3-METHYLPIPERIDINE	C23H27Br2NO3
3-(HYDROXYMETHYL)-PIPERIDINE	C23H27Br2NO4
1,2,3,4-TETRAHYDROISOQUINOLINE	C26H25Br2NO3
2-ETHYLPIPERIDINE	C24H29Br2NO3
3,4-DICHLORO-N-ETHYLBENZYLAMINE	C26H25Br2Cl2NO3
2-METHYLPYRROLIDINE	C22H25Br2NO3
N-ETHYL-N-PROPYLAMINE	C22H27Br2NO3
4-METHYLPIPERIDINE	C23H27Br2NO3
(S)-(+)-2-(METHOXYMETHYL)PYRROLIDINE	C23H27Br2NO4

N-BENZYLETHANOLAMINE	C26H27Br2NO4
DIBENZYLAMINE	C31H29Br2NO3
4-BENZYL-4-HYDROXYPIPERIDINE	C29H31Br2NO4
(R)(-)-2-BENZYLAMINO-1-BUTANOL	C28H31Br2NO4
N-(N-ETHYLAMINOACETYL)-2,6-DIMETHYLANILINE	C29H32Br2N2O4
N-ETHYL-O-METHOXYBENZYLAMINE	C27H29Br2NO4
MAYBRIDGE NRB 01961	C30H33Br2NO5
2-((N-ETHYLAMINO)METHYL)-4-NITROPHENOL	C26H26Br2N2O6
MAYBRIDGE SEW 01484	C31H28Br2NO4S
3-AZABICYCLO-[3.2.2]NONANE	C25H29Br2NO3
N-(2-METHOXY-ETHYL)ETHYLAMINE	C22H27Br2NO4

Blunt
18. (Original) The compound as defined in Claim 1 which is

D-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]valine,
D-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]leucine,
L-S-Benzyl, N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]cysteine,
D-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]tyrosine,
L-N-d-(2,2,5,7,8-Pentamethylchroman-6-sulfonyl),
N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]arginine,
L-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]aminobutyric acid,
L-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]valine,
L-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]leucine,
L-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]proline,
L-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]cysteine,
N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]glycine,
L-N-a-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]lysine,
D-N-a-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]lysine,
N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]aminoisobutyric acid,
L-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]phenylglycine,
D-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]phenylglycine,
N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]sarcosine,
DL-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]-a-methylphenylalanine,
L-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]isoleucine,
D-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]methionine,
L-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]methionine,

BLX


L-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]phenylalanine,
D-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]phenylalanine,
L-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]cyclohexylalanine,
L-N-e-(Benzylloxycarbonyl), N-a-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)-
benzoyl]lysine,
D-N-e-(Benzylloxycarbonyl), N-a-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)-
benzoyl]lysine,
D-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]homoserine,
N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]glycine,
N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]sarcosine,
3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)phenylformylimino diacetic acid,
N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]-beta-alanine,
N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]-beta-alanine,
D-N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]methionine.
L-N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]serine
D-N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]serine
N-[3,5-Dichloro-4-(4-hydroxy-3-bromophenoxy)benzoyl]glycine
N-[3,5-Dichloro-4-(4-hydroxy-3-methylphenoxy)benzoyl]glycine
N-[3,5-Dichloro-4-(4-hydroxy-3-ethylphenoxy)benzoyl]glycine

19. (Original) The compound as defined in Claim 1 which is







D-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]methionine,
L-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]methionine,
D-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl] a-methylalanine,
D-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]asparagine,
L-Methyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]alanine,
L-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]alanine,
L-Dimethyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamate,
L-Dimethyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamate;
*L-(O-*tert*-butyl)methyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]*
glutamate,

L-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamic acid,
L-N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]aspartic acid,
D-di-*tert*-butyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamate,
D-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamic acid,
L-O-*tert*-Butyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamine,
L-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamine,
D-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamine,
L-O-Benzyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]aspartic acid,
L-O-*tert*-Butyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]asparagine,
L-Methyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]homoserine,
L-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]homoserine,
D-Methyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]homoserine,
BK
CM


and the compounds showed in the table below,



R	Mol. Formel
L-Val	C ₂₂ H ₂₅ Br ₂ NO ₅
L-Val	C ₂₂ H ₂₅ Br ₂ NO ₅
L-Tyr	C ₂₆ H ₂₅ Br ₂ NO ₆
	C ₂₃ H ₂₇ Br ₂ NO ₅
	C ₂₇ H ₂₇ Br ₂ NO ₅ S


D-Leu	C23H27Br2NO5
D-Tyr	C26H25Br2NO6
D-Trp	C28H26Br2N2O5
L-Arg	C23H28Br2N4O5
L-Abu	C21H23Br2NO5
	C20H21Br2NO5
	C20H21Br2NO5
L-Leu	C23H27Br2NO5
	C25H23Br2NO5
D-Pro	C22H23Br2NO5
L-Ile	C23H27Br2NO5
	C23H25Br2NO5
L-Phe	C26H25Br2NO5
L-Lys	C23H28Br2N2O5
	C23H25Br2NO5
L-Pro	C22H23Br2NO5
	C25H23Br2NO5

20. (Original) The compounds as defined in Claim 1 having the structures




or a pharmaceutically acceptable salt or ester(s) thereof.

21. (Original) The compounds as defined in Claim 1 having the structures



or a pharmaceutically acceptable salt or ester(s) thereof.

22. (Original) The compounds as defined in Claim 1 having the structures



wherein R₁= isopropyl, methyl, ethyl; R₂ and R₃ may be independently selected from Br, Cl and Me; n=0 or 1; R* may be hydrogen, alkyl, cycloalkyl, aryl and heteroaryl; * denotes either D or L stereochemistry when R* is not hydrogen; R₅ is hydrogen; and R' is selected from hydrogen, lower alkyl, especially ethyl and methyl.

23. (Currently Amended) A method for preventing, inhibiting or treating a disease associated with metabolism dysfunction, or which is dependent on the expression of a T₃ regulated gene, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound as defined in Claim 1.

24. (Original) The method as defined in Claim 23 wherein the disease associated with metabolism dysfunction or which is dependent on the expression of a T₃ regulated gene is obesity, hypercholesterolemia, atherosclerosis, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer, glaucoma, cardiac arrhythmia, congestive heart failure, or skin disorders.

Claims 25.-26. (Cancelled)

27. (Original) A pharmaceutical composition comprising an effective amount of a compound according to Claim 1 or a pharmaceutically effective salt thereof, together with a pharmaceutically acceptable carrier.

28. (Original) The method according to Claim 24 in which the skin disorder or disease is dermal atrophy, post surgical bruising caused by laser resurfacing, keloids, stria, cellulite, roughened skin, actinic skin damage, lichen planus, ichtyosis, acne, psoriasis, Dernier's disease, eczema, atopic dermatitis, chloracne, pityriasis and skin scarring.

29. (Currently Amended) A method to treat skin disorder or disease ~~by the use comprising the step of administering to a patient a therapeutically effective amount~~ of a compound of Claim 1 in combination with a retinoid or a vitamin D analog.